Gamma-aminobutyric acid-producing lactobacilli positively affect metabolism and depressive-like behaviour in a mouse model of metabolic syndrome by Patterson, E. et al.
1Scientific RepoRtS |         (2019) 9:16323  | https://doi.org/10.1038/s41598-019-51781-x
www.nature.com/scientificreports
Gamma-aminobutyric acid-
producing lactobacilli positively 
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metabolic syndrome
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Metabolic and neuroactive metabolite production represents one of the mechanisms through which 
the gut microbiota can impact health. One such metabolite, gamma-aminobutyric acid (GABA), can 
modulate glucose homeostasis and alter behavioural patterns in the host. We previously demonstrated 
that oral administration of GABA-producing Lactobacillus brevis DPC6108 has the potential to increase 
levels of circulating insulin in healthy rats. Therefore, the objective of this study was to assess the 
efficacy of endogenous microbial GABA production in improving metabolic and behavioural outcomes 
in a mouse model of metabolic dysfunction. Diet-induced obese and metabolically dysfunctional 
mice received one of two GABA-producing strains, L. brevis DPC6108 or L. brevis DSM32386, daily for 
12 weeks. After 8 and 10 weeks of intervention, the behavioural and metabolic profiles of the mice 
were respectively assessed. intervention with both L. brevis strains attenuated several abnormalities 
associated with metabolic dysfunction, causing a reduction in the accumulation of mesenteric adipose 
tissue, increased insulin secretion following glucose challenge, improved plasma cholesterol clearance 
and reduced despair-like behaviour and basal corticosterone production during the forced swim test. 
Taken together, this exploratory dataset indicates that intervention with GABA-producing lactobacilli 
has the potential to improve metabolic and depressive- like behavioural abnormalities associated with 
metabolic syndrome in mice.
The obesity and metabolic dysfunction pandemic currently underway represents one of the most serious global 
health challenges of the 21st century. According to the World Health Organization (WHO) in 2016, more than 
1.9 billion adults were overweight, and of these, over 650 million were obese1. Attempts to curb this significant 
public health issue by creating efficacious primary and secondary prevention strategies have been largely unsuc-
cessful due to the multifaceted nature of this disease. Failure in compliance with lifestyle interventions, coupled 
with novel environmental stressors, has rendered the global population susceptible to this pandemic. As a result, 
metabolic surgery is currently the most effective therapy for morbid obesity and metabolic disturbances2. This 
has driven the demand for researchers to investigate novel, non-invasive therapies for obesity and its associ-
ated sequelae. While significant inroads have been made in unravelling the biochemical and endocrinological 
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underpinnings of obesity and its related comorbidities, derived translational therapeutic interventions have been 
sparse or are often limited by their side-effects3.
The composition, diversity and functionality of the gut microbiota are substantially discordant between 
healthy and obese subjects4–6. Thus, the gut microbiota has become a popular target for novel therapies directed 
towards obesity and diabetes, one which by-passes the need for significant lifestyle changes or surgery. Indeed, 
consumption of a high-fat (HF) diet and increased energy intake predisposes mice7 and humans8 to a low-grade 
inflammation, insulin resistance and considerable shifts in the microbiota. In turn, circulating bacterial particles 
such as lipopolysaccharide (LPS)9,10 are increased and trigger the host inflammatory immune response in tissues 
such as the liver and adipose tissue7,11. Furthermore, mice subcutaneously infused with LPS display increased 
susceptibility to weight gain and inflammation11,12. It is therefore plausible that changes in the composition of 
the gut microbiota may be intrinsically linked to the pathogenesis of obesity and related metabolic dysfunction.
Certain microbial therapeutics have proven efficacious in improving several physiological abnormalities 
associated with obesity and metabolic dysfunction in both preclinical13–17 and clinical studies18,19. As such, spe-
cific bacterial strains and their metabolites may be considered adjunct therapies for certain metabolic disorders. 
Microbial metabolites, such as short chain fatty acids and neuroactives, may be central to this effect. One such 
neurotransmitter produced by certain bacteria is gamma-aminobutyric acid (GABA), the primary inhibitory 
neurotransmitter in the central nervous system. Additionally, evidence suggests that this neurotransmitter may 
have a therapeutic role in treating type-1-diabetes (T1D) and long-standing type-2-diabetes (T2D) in which the 
pancreatic β-cells become fatigued. Activation of the GABAA and GABAB receptors expressed on β-cells has been 
shown to stimulate insulin secretion and induce β-cell proliferation20–22. Moreover, the GABAA receptor is widely 
expressed on CD4+ T cells and several studies have indicated a putative immunomodulatory role of this neuro-
transmitter, suggesting an alternative mechanism through which it may impact upon systemic inflammation and 
the autoimmunity of T1D23,24.
Peripheral inflammation associated with obesity and metabolic dysfunction enhances the risk for neuropsy-
chiatric and neurological disorders (for reviews see25,26). It has been shown that obese and T2D (db/db) mice dis-
play enhanced anxiety-like behaviour and impaired spatial recognition memory27,28, and we now understand that 
the gut microbiota plays a central role in gut-brain signalling which can impact brain physiology, function and 
behaviour29. In line with this, convincing pre-clinical evidence has demonstrated that enteric microbial GABA 
production can mediate physiological and behavioural effects via the vagus nerve30. However, little probing has 
been done into the behaviour-modifying attributes of GABA-secreting microbes in the context of obesity.
We previously isolated L. brevis DPC6108 from an infant faecal sample and L. brevis DSM32386 from a tra-
ditional Italian cheese, and demonstrated their ability to produce GABA in vitro31,32. We also explored the effects 
of intervention with L. brevis DPC6108 on the metabolic profile of two different rodent models; healthy and 
streptozotocin-induced T1D rats33. The aim of the present study was to assess whether microbial GABA pro-
duction could attenuate the metabolic dysfunction observed in diet-induced obese mice. In addition, we aimed 
to determine whether microbial GABA production could attenuate impairments in the neuropsychiatric behav-
ioural profile observed in these mice and associated with metabolic dysfunction.
Results
Survival of L. brevis DPC6108 and DSM32386 following gastrointestinal transit. Quantification 
of the number of colony forming units (CFUs) of administered rifampicin-resistant L. brevis DPC6108 and 
DSM32386 in the faeces of mice confirmed survival following gastrointestinal transit. Faecal recovery of L. brevis 
DPC6108 was ~2 × 109 and L. brevis DSM32386 was ~1 × 109 CFU/g faeces after two weeks and remained at 
similar numbers following four weeks of intervention. Colonies isolated from the plates were tested for GABA 
production to assess if gastrointestinal transit affected the ability of L. brevis DPC6108 and DSM32386 to produce 
GABA in vitro. Pooled fresh faecal samples collected from each cage of mice in DPC6108 and DSM32386 (4 cages 
per group) were analysed in duplicate following two and five weeks of intervention. At two and five weeks of inter-
vention, bioconversion of MSG to GABA by DPC6108 was 68% and 83%, respectively (MRS containing 1% (w/v) 
MSG). At two and five weeks of intervention, bioconversion of MSG to GABA by DSM32386 was 66% and 78%, 
respectively. All colonies tested which were isolated from faecal samples had a similar percentage conversion of 
MSG to GABA. The average bioconversion of the wild-type DPC6108 and DSM32386 strains were 77% and 56% 
respectively. However, these averages are based on triplicates taken at one time-point only during the study and 
previous experimental analyses comparing the GABA-producing capabilities of these strain revealed no major 
differences between the wild-type strains. No significant differences were observed in the GABA-producing capa-
bilities between the strains which had passed gastrointestinal transit compared to the wild-type strains.
Intervention with GABA-producing microbes affected adipose deposition following HF diet. 
Following 12 weeks of HF feeding, there were no significant differences in bodyweight gain over the intervention 
period between the HF groups (Fig. 1B). L. brevis DPC6108 (p < 0.01) and DSM32386 (p < 0.05) were asso-
ciated with reduced quantity of mesenteric adipose tissue (MAT), compared with the high fat control (HFC; 
Fig. 1C). Both DPC6108 (p < 0.001) and DSM32386 (p < 0.05) reduced percentage body fat, compared with the 
HFC (Fig. 1D). There were no differences in final bodyweight observed between the groups consuming the HF 
diet (F2,38 = 0.108, p > 0.05; Fig. 1E). As expected, there was a significant difference in final bodyweight between 
the low fat control (LFC) and the HFC (p < 0.001; Fig. 1E).
L. brevis DSM32386 improved HF diet-induced glucose intolerance and impaired insulin sensitivity. 
After 12 weeks of HF feeding and prior to intervention with L. brevis (Fig. 1A), diet-induced hyperglycaemia 
and insulin insensitivity was confirmed in a subset of mice from the HFC, compared with a subset of mice from 
the LFC (Fig. 2A–D). After 12 weeks of HF feeding, the intraperitoneal glucose tolerance test (IP-GTT) revealed 
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that HF-fed mice had higher blood glucose levels at 15 (t6.804 = 4.432 p < 0.01), 30 (t5.520 = 9.949, p < 0.001), 
60 (t6.580 = 13.1, p < 0.001), 90 (t10 = 9.854, p < 0.001) and 120 (t5.692 = 7.326, p < 0.001); Fig. 2A) minutes, and 
a higher area under the curve (AUC) for glucose (t6.226 = 10.976, p < 0.001; Fig. 2B) compared with the LFC, 
indicating the impaired ability of HF-fed mice to respond to the glucose challenge. The intraperitoneal insulin 
tolerance test (IP-ITT) revealed that HF-fed mice were insensitive to exogenous insulin compared with the LFC 
(t7.364 = 3.783, p < 0.01; Fig. 2D). Therefore, 12 weeks of feeding with the HF diet was deemed sufficient to induce 
glucose intolerance (Fig. 2A,B) and insulin insensitivity (Fig. 2C,D), prior to microbial interventions.
Following an additional 10 weeks HF feeding in combination with L. brevis DPC6108 and L. brevis 
DSM32386, all mice underwent IP-GTT (Fig. 2E,F) and IP-ITT (Fig. 2G,H). After 22 weeks HF feeding, repeat 
IP-GTT revealed that mice in the HFC had higher fasting blood glucose levels at 0 (t12 = 3.077 p = 0.01), 15 
(t7.046 = 10.358 p < 0.001), 45 (t12 = 8.101 p < 0.001), 90 (t7.856 = 3.173 p < 0.05) and 120 (t12 = 3.179 p < 0.01) 
minutes post-glucose load, compared with the LFC (Fig. 2E). The HFC also had a higher AUC for glucose 
(t6.579 = 7.137 p < 0.001), compared with the LFC (Fig. 2F). Somewhat in line with the results for the IP-GTT 
when comparing between HFC and LFC, the IP-ITT revealed a significant effect of HF diet on blood glucose 
levels at 0 (t12 = 2.930 p < 0.05) and 15 (t12 = 5.550 p < 0.001) minutes post-insulin challenge, compared with the 
LFC (Fig. 2G). There was only a marginally significant effect on the AUC for glucose between the HFC and LFC 
(t12 = 2.160 p = 0.052; Fig. 2H).
The microbial interventions had a significant effect overall on blood glucose levels at 15 (F3,32 = 7.390, p < 0.01) 
and 45 (F3,32 = 6.072, p < 0.01) minutes post-glucose load, compared with the HFC (Fig. 2E). DSM32386 mice dis-
played lower blood glucose levels at 15 (p < 0.05) and 45 (p < 0.01) minutes post-glucose load, compared with the 
HFC (Fig. 2E). There was a significant effect overall of the interventions on the AUC for the IP-GTT (F2,32 = 6.016, 
p < 0.01; Fig. 2F) and it was revealed that DSM32386 was the only intervention to significantly improve the ability 
to clear blood glucose following glucose challenge (p = 0.01; Fig. 2F). In line with this, the microbial interventions 
had a significant effect overall on blood glucose levels at 0 (F3,32 = 11.452, p < 0.001), 15 (F3,32 = 13.146, p < 0.001), 
45 (F3,32 = 16.118, p < 0.001) and 120 (F3,32 = 8.776, p = 0.001) minutes post-insulin load during the IP-ITT, com-
pared with the HFC (Fig. 2G). DSM32386 had lower blood glucose levels at 0 (p < 0.01), 15 (p < 0.001) and 120 
(p = 0.001) minutes post-insulin load, compared with the HFC (Fig. 2G). DPC6108 had lower blood glucose 
levels at 0 (p < 0.001) and 45 (p < 0.05) minutes post-insulin load, compared with the HFC (Fig. 2G). Overall, 
Figure 1. L. brevis reduced fat mass and distribution of adiposity after 12 weeks of intervention. (A) Schematic 
figure representing mouse trial design and timeline for procedures, with high-fat diet represented by the 
black arrow and treatments in a 12-week intervention represented by coloured arrows. (B) Bodyweight gain 
throughout the pre-feeding (white background) and intervention (red background) for n = 14 mice per group. 
(C) Adipose tissue mass and distribution across EAT, SAT and MAT and (D) Fat and lean body composition. 
(E) Final body weight after 24-week feeding (HFC; n = 13 and LFC; n = 10) and 12-week intervention with 
DPC6108 (n = 14) and DSM32386 (n = 14). Data are expressed as mean ± SEM. Bodyweight data were analysed 
using the mixed model ANOVA. Tukey’s post-hoc test was applied. All other data were analysed using the 
appropriate unpaired student t-test (HFC vs LFC) and one-way analysis of variance (ANOVA). ###p < 0.001 
HFC vs LFC, *p < 0.05 treatment vs HFC, and **p < 0.01 treatment vs HFC. IP-GTT: intraperitoneal glucose 
tolerance test, IP-ITT: insulin tolerance test, EPM: elevated plus maze, FST: forced swim test, OF: open field, 
NOR: novel object recognition, MMG: mixed meal gavage, NMR: nuclear magnetic resonance, HFC: high fat 
control, DPC6108: L. brevis DPC6108, DSM32386: L. brevis DSM32386, LFC: low fat control, EAT: epididymal 
adipose tissue, SAT: subcutaenous adipose tissue and MAT: mesenteric adipose tissue. Figure 1A was created 
with BioRender.com.
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intervention with both L. brevis strains had a significant effect on total AUC during the IP-ITT (F2,32 = 14.408, 
p < 0.001; Fig. 2H) and DSM32386 improved insulin sensitivity (p = 0.001; Fig. 2H).
Plasma was collected during T0 and T15 of the IP-GTT to measure insulin and, subsequently, insulin resist-
ance index (Fig. 2I,J). At 0 minutes, before glucose load, there was an overall effect of L. brevis on plasma insu-
lin (F2,30 = 5.46, p = 0.01; Fig. 2I). Intervention with DSM32386 increased resting plasma insulin at 0 minutes 
(p < 0.01), compared with the HFC (Fig. 2I). Insulin production 15 minutes post glucose load was higher in both 
microbial interventions (DPC6108; p < 0.001 and DSM32386 (p < 0.001), compared with the HFC (Fig. 2I). No 
differences in the insulin resistance index were observed following microbial intervention, compared with the 
HFC (Fig. 2J).
GABA-producing microbes improved post-prandial cholesterol metabolism. Assessment of the 
plasma at T0, prior to the mixed meal gavage (MMG) challenge indicated that microbial intervention had a 
significant impact on fasted plasma cholesterol levels (F2,32 = 6.931, p < 0.01), compared with the HFC (Fig. 2K). 
Post-hoc analysis revealed DPC6108 (p < 0.01) and DSM32386 (p < 0.01) reduced cholesterol levels at T0, com-
pared with the HFC (Fig. 2K). No significant impact of intervention on plasma cholesterol was identified at two 
or four hours post-MMG; however, at 18 hours DPC6108 (p < 0.001) and DSM32386 (p < 0.001) both displayed 
reduced cholesterol levels, compared with the HFC (Fig. 2K). There was a significant effect overall of microbial 
Figure 2. L. brevis DSM32386 improved glucose clearance in the IP-GTT while both strains improved glucose-
dependent insulin secretion following glucose challenge in the IP-ITT. HFC (n = 7) and LFC (n = 7) mice were 
assessed for 1 g/Kg glucose (IP-GTT; A,B) and 0.75 IU/Kg insulin (IP-ITT; C,D) glycaemic responses following 
12 weeks of feeding, prior to commencement of treatments at week 13. At week 24 of feeding and after 10 weeks 
of intervention, LFC (n = 7), HFC (n = 7), DPC6108 (n = 14), and DSM32386 (n = 14) mice were assessed for 
glycaemic responses to glucose (E,F) and insulin (G,H) challenges. Plasma insulin concentration as determined 
from samples collected at T = 0 and T = 15 during glucose challenge for LFC (n = 7), HFC (n = 5), DPC6108 
(n = 14) and DSM32386 (n = 12) (I) and insulin resistance index determined by multiplying the area under the 
curve of both the blood glucose (0 to 120 min) and the plasma insulin (0 to 15 min) obtained following glucose 
challenge (J). At week 24 of feeding and after 10 weeks of intervention LFC (n = 7), HFC (n = 7), DPC6108 
(n = 14), DSM32386 (n = 14) mice were assessed for cholesterol metabolism by oral gavage with a complete 
meal, Ensure Plus, Abbott Nutrition. Total plasma cholesterol was measured at T = 0, T = 2, T = 4 and T18 
hr post-gavage (K). Total AUC for cholesterol metabolism was calculated from individual time points for all 
groups (L). Data are expressed as mean ± SEM. All data was analysed using the appropriate unpaired student 
t-test (HFC vs LFC) and one-way analysis of variance (ANOVA). #p < 0.001 HFC vs LFC, ##p < 0.001 HFC vs 
LFC and ###p < 0.001 HFC vs LFC, *p < 0.05 treatment vs HFC, **p < 0.01 treatment vs HFC and ***p < 0.001 
treatment vs HFC. AUC: area under curve, HFC: high fat control, DPC6108: L. brevis DPC6108, DSM32386: L. 
brevis DSM32386, LFC: low fat control.
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intervention on total AUC for plasma cholesterol throughout the MMG (F2,13.573 = 14.547, p < 0.001, Fig. 2L). 
DPC6108 (p < 0.001) and DSM32386 (p < 0.001) significantly reduced plasma cholesterol levels, compared with 
the HFC (Fig. 2L).
GABA-producing microbes increased luminal GABA levels in the small intestinal content. Diet 
had no impact on either adipose tissue (t15.738 = 1.522) or small intestinal content (t20 = −0.898) of GABA, 
between the HFC and LFC groups (Fig. 3A,B). This was unsurprising as both diets were matched for amino acid 
profiles. L. brevis did have a significant impact on small intestinal content of GABA (F2,20.551 = 6.906, p < 0.001), 
compared with the HFC (Fig. 3B). While intervention with DPC6108 had a tendency to increase luminal contents 
of GABA (p = 0.067), DSM32386 significantly increased GABA (p < 0.01) in the small intestine, compared with 
the HFC (Fig. 3B).
GABA-producing microbes had little effect on host plasma metabolome. Targeted analysis of 
140 metabolites from the plasma metabolome taken from fasted mice unveiled modest metabolic alterations as a 
result of microbial intervention. Figure 4A depicts a sparse partial least square discriminant analysis (sPLS-DA) 
plot, with the metabolites most important to the model displayed in the loadings plot (Fig. 4B). DPC6108 had 
little impact on the plasma metabolome, solely increasing the biogenic amine ornithine when compared with the 
HFC (q < 0.05; Fig. 4C). DSM32386 also increased ornithine compared with the HFC (q < 0.05; Fig. 4C), while 
decreasing arginine compared to both the HFC and DPC6108 (q < 0.01; Fig. 4D).
Diet and GABA-producing microbes had a significant impact on gut microbial composition 
and diversity. A total of 51 faecal samples were subjected to 16S metataxanomic analysis. Illumina sequenc-
ing generated a total of 2,560,853 high quality sequences. After rarefying the sequencing depth, Chao 1 diver-
sity index and observed operational taxonomy units (OTU) were calculated (Supplementary Table S2). Chao 
1 index showed a higher diversity profile in the LFC (mean value = 4,397.0, p < 0.05) and DPC6108 (mean 
value = 4,138.5, p < 0.05), compared with the HFC. Moreover, DPC6108 showed higher diversity, compared with 
the HFC. The data show that there was a significant difference in the richness, with reduced numbers of OTUs 
in all HF diet-fed groups, compared with the LFC; although the number of OTUs was increased in DPC6108, 
compared with the HFC. To assess beta-diversity, Bray-Curtis distance matrix was calculated and differences 
were identified between LFC (p < 0.001) and DSM32386 (p < 0.05), compared with the HFC (Supplementary 
Table S2).
At phylum level, all groups demonstrated comparable microbial compositions (Fig. 5A). In LFC, Firmicutes 
(43.8%) and Bacteroidetes (44.3%) were dominant (ratio Firmicutes/Bacteroides = 0.98). The phylum 
Deferribacteres (6.1%) was significantly higher in LFC, compared with all HF diet-fed groups. A reduction of 
Deferribacteres (1.7%, p < 0.001) and increase of Firmicutes (52.3%, p < 0.05) was observed in the HFC, com-
pared with the LFC. HFC, DSM32386 and DPC6108 mice had similar relative abundance of Firmicutes and 
Figure 3. L. brevis increased GABA levels in small intestinal content. GABA levels were determined from tissue 
samples collected at the end of the 12-week intervention from LFC (n = 8), HFC (n = 12), DPC6108 (n = 14), 
DSM32386 (n = 11) from epididymal adipose tissue (A) and from LFC (n = 10), HFC (n = 12), DPC6108 
(n = 14), DSM32386 (n = 14) in total small intestinal content (B). Data are expressed as mean ± SEM. All data 
was analysed using the appropriate unpaired student t-test (HFC vs LFC) and one-way analysis of variance 
(ANOVA). ###p < 0.001 HFC vs LFC, **p < 0.01 treatment vs HFC. AUC: area under curve, GABA: gamma-
aminobutyric acid, HFC: high fat control, DPC6108: L. brevis DPC6108, DSM32386: L. brevis DSM32386, LFC: 
low fat control.
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Bacteroidetes (ratio Firmicutes/Bacteroides HFC = 1.28, DSM32386 = 1.22, DPC6108 = 1.30), while the relative 
abundance of Deferribacteres was higher in DSM32386 (2.7%, p = 0.09) and DPC6108 (2.9%, p = 0.08), com-
pared with the HFC (1.7%).
At the genus level (Fig. 5B), Akkermansia was higher in the LFC (0.02%), compared with the HFC (0.01%; 
p < 0.0001), but absent in both DSM32386 and DPC6108. A higher abundance of Odoribacter (6.02%) and a 
lower abundance of Lachnoclostridium (3.57%) were detected in the LFC, compared with the HFC (Odoribacter 
p < 0.001, Lachnoclostridium p = 0.01), DSM32386 (Odoribacter p < 0.05, Lachnoclostridium p = 0.05) and 
DPC6108 (Odoribacter p < 0.001). Oscillospira and Clostridiales_other were higher in the HFC (Oscillospira 
p = 0.01, Clostridiales_other p < 0.01), DSM32386 (Oscillospira p < 0.01, Clostridiales_other p = 0.001) and 
DPC6108 (Oscillospira p < 0.05, Clostridiales_other p < 0.001), compared with the LFC (1.17%, 9.07%, 2.43%, 
respectively). All sequences associated to the genus Lactobacillus were blasted manually on the NCBI Basic Local 
Alignment Search Tool and the species L. brevis was detected only in DSM32386 and DPC6108 groups.
Figure 4. L. brevis altered plasma ornithine and arginine. (A) Sparse partial least square discriminant 
analysis (sPLS-DA) plot displays HFC (n = 10; red), DPC6108 (n = 10; green) and DSM32386 (n = 10; 
purple) samples. (B) Plot metabolite loadings graph displaying key metabolite differences between groups. 
Quantitative data is displayed for the metabolites which were significantly altered by DPC6108 or DSM32386; 
this included the biogenic amine ornithine (C) and amino acid arginine (D). Orn:Ornithine, Arg:Arginine, 
Met-SO:Methioninesulfoxide, Glu:Glutamate, alpha AAA:alpha Aminoadipic Acid, Met:Methionine, 
Phe:Phenylalanine, Gln:Glutamine, HFC: high fat control, DPC6108: L. brevis DPC6108, DSM32386: L. brevis 
DSM32386. *q < 0.05 treatment vs HFC, **q < 0.01 treatment vs HFC. Plots depict individual replicates with 
mean and SEM.
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Bifidobacterium, Erysipelotrichaceae, Muribaculum and Odoribacter were related to reduced 
glycaemia and cholesterolaemia. The principal component analysis (PCA) plot (Fig. 5C) and corre-
lation matrix (Fig. 5D) were generated based on the relative microbial composition and metabolic parame-
ters. Correlations between microbiota and biochemical analyses revealed that the increase of certain microbial 
taxa corresponded to the improvement or deterioration of glycaemia (after IP-GTT or IP-ITT), insulin or 
cholesterol levels (Supplementary Table S3). Indeed, diet appeared to be the primary determinant of these 
microbiota-biochemistry associations, as both are known to be substantially impacted by such factors. The PCA 
scores clearly separated the LFC from the HF groups, with DSM32386 and DPC6108 clustering together away 
from the HFC (Fig. 5C). PCA1 and PCA2 explained the 21.42% and 15.0% of variance between groups, respec-
tively. The variance associated to the LFC was related to Erysipelotrichaceae, Muribaculum and Bifidobacterium 
on PCA1 (|loadings| ≥ 0.52), and Bifidobacterium on PCA2 (|loadings| ≥ 0.52). The variance associated to 
DSM32386 and DPC6108 was related to Odoribacter, cholesterol (T0, T2 and T4), glycaemia under IP-GGT (at 
T0, T15, T45, T120) on PCA1 (|loadings| ≥ 0.50) and Alistipes, other Bacteroidetes, and resting insulin on PCA2 
(|loadings| ≥ 0.64), apart from four samples belonging to DPC6108 (Fig. 5D).
GABA-producing microbes improved depression-like behaviour and basal corticosterone lev-
els during the forced swim test (FST). Diet and bodyweight impacted immobility time during the FST. 
Mice in the HFC group spent more time immobile, compared with the LFC (t21 = 4.245, p < 0.001; Fig. 6A). 
While it was hypothesised that obesity itself impaired mobility in the HFC, data from the novel object recog-
nition (NOR)/open field test would suggest that bodyweight had no significant effect on mobility (Fig. S2D). 
Therefore, depression-like behaviour was induced through consumption of the HF diet. L. brevis had an overall 
impact on immobility time during the FST (F2,36 = 19.474, p < 0.001), compared with the HFC (Fig. 6A). Post-hoc 
analysis revealed that DPC6108 (p < 0.001) and DSM32386 (p < 0.001) reduced the duration of time spent immo-
bile during the FST, compared with the HFC (Fig. 6A). In addition, mice in the HFC group produced more faecal 
pellets during the FST (t24 = 3.021, p < 0.05), compared with the LFC, indicative of enhanced anxiety during this 
Figure 5. Both diet and L. brevis had a significant impact on gut microbiota composition. Relative abundance 
of microbial taxa at (A) phylum and (B) genus level. Phyla and genera representing <0.1% abundance in any 
sample were considered as Other. The PCA plot based on OTU relative abundances of the bacterial community 
and the metabolic parameters measured in mice (C). The first two principal coordinates (PC1 and PC2) 
are plotted for each sample (D), with the variables related to the variance between groups. PCA: Principal 
Component Analysis, OTU; Operational Taxonomy Unit.
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test (Fig. 6B). Finally, DSM32386 produced significantly fewer faecal pellets during the FST (p < 0.01), compared 
with the HFC (Fig. 6B).
Plasma was isolated from individual mice at 0 minutes pre-FST, then at 15, 45, 90 and 120 minutes post-FST to 
assess the impact of diet and microbial intervention on the hypothalamic-pituitary-adrenal (HPA) axis response 
to stress. Basal corticosterone levels were increased in the HFC, compared with the LFC (t23 = 3.619, p < 0.01; 
Fig. 6C). Interestingly, L. brevis restored basal corticosterone to levels comparable with the LFC and prevented 
the apparent HF dietary stimulation of the HPA axis and the stress response (F2,36 = 16.110, p < 0.001; Fig. 6C). 
DPC6108 (p < 0.001) and DSM32386 (p < 0.001) reduced basal corticosterone levels, compared with the HFC 
(Fig. 6C).
Following the FST, the HFC had higher levels of corticosterone at 15 (t21 = 4.104, p < 0.001) and 45 (t22 = 6.692, 
p < 0.001) minutes, compared with the LFC (Fig. 6D). In addition, DPC6108 at 45 (p = 0.001), and DSM32386 at 
15 (p < 0.01) and 45 (p < 0.01) minutes post-FST displayed higher corticosterone levels, compared with the HFC 
(Fig. 6D).
Diet and bodyweight affected mobility, while GABA-producing microbes had no effect on anx-
ious behaviour. Diet and bodyweight had a significant impact on mobility, represented by total distance trav-
elled during the aversive open-field (OF) test (Fig. S1A). Mice in the HFC group travelled significantly less in the 
open arena, compared with the LFC (t24 = 3.678, p < 0.01; Supplementary Fig. S1A). L. brevis had no impact on 
the total distance travelled, compared with the HFC (Supplementary Fig. S1A). There was no effect of diet (HFC 
vs LFC) on duration of time spent in inner (Supplementary Fig. S1B) or outer (Supplementary Fig. S1C) zones 
of the aversive OF. In addition, L. brevis had no effect on the duration of time spent in inner (Supplementary 
Fig. S1B) and outer zones (Supplementary Fig. S1C) of the OF. There was no effect of diet (HFC vs LFC) on faecal 
Figure 6. L. brevis improved symptoms of depression-like behaviour in the FST and resting corticosterone 
levels. The effect of HF-diet feeding and L. brevis intervention on depression-like behaviour and the HPA axis 
response to stress was assessed after 21 weeks of feeding and after 8 weeks of intervention. Despair behaviour 
was assessed thorough immobility time (A) by mice throughout the test and anxiety-like behaviour was 
assessed through the number of faecal pellets produced during the test (B). Plasma isolated at T = 0, just prior 
to the FST was used to measure corticosterone production (C) and subsequent plasma samples collected at 
T = 15, T = 45, T = 90 and T = 120 post-FST were used to calculate corticosterone as a measure of the HPA axis 
response to stress (D). Samples were collected from mice in LFC (n = 13), HFC (n = 12), DPC6108 (n = 11), 
DSM32386 (n = 14). All data was analysed using the appropriate unpaired student t-test (HFC vs LFC) and 
one-way analysis of variance (ANOVA). #p < 0.05 HFC vs LFC, ##p < 0.01 HFC vs LFC and ###p < 0.001 HFC 
vs LFC, **p < 0.01 treatment vs HFC and ***p < 0.001 treatment vs HFC. FST: forced swim test, HF: high fat, 
HFC: high fat control, HPA: hypothalamic pituitary adrenal, DPC6108: L. brevis DPC6108, DSM32386: L. brevis 
DSM32386, LFC: low fat control.
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pellet production in the aversive OF test (t(24) = 0.5527, p = 0.5856). In addition, L. brevis had no effect on faecal 
pellet production (F (2, 40) = 0.923, p = 0.406).
In contrast, diet and bodyweight did not impact mobility, represented by total distance travelled during the OF 
test conducted during the habituation phase (Day 1) of the NOR test. In this open arena, there was no difference 
in mobility between the HFC and LFC (Supplementary Fig. S1D). L. brevis had a significant impact on distance 
travelled during this test (F2,38 = 8.911, p < 0.001; Supplementary Fig. S1D) and it was revealed that DPC6108 
increased total distance travelled, compared to the HFC (p < 0.001; Supplementary Fig. S1D). There was no effect 
of diet on duration of time spent in inner (Supplementary Fig. S1E) or outer (Supplementary Fig. S1F) zones of 
the NOR open field arena, between the HFC and LFC. Similarly, L. brevis had no effect on time spent in inner 
(Supplementary Fig. S1E) or outer (Supplementary Fig. S1F) zones of the NOR open field arena.
L. brevis DSM32386 had a modest effect on cognitive function during the NOR test. During 
day two of the NOR test, all groups spent equal proportions of time investigating the two identical objects (A and 
B) within the open arena (Supplementary Fig. S2A). During day three, following introduction of a novel object 
in the space which was previously allocated to object B, while all mice increased the interaction time spent with 
the novel object, the effect was only significant following intervention with DSM32386 (t(26) = 3.317, p < 0.01; 
Supplementary Fig. S2B). There was no impact of diet or L. brevis on the ability of mice to discriminate between 
the novel and familiar objects, as reflected in the discrimination index (F(2,40) = 1.514, p = 0.233) (Supplementary 
Fig. S2C).
GABA-producing microbes had no impact on anxiety-like behaviour during the elevated plus 
maze (EPM) test. In all aspects on the EPM test, there was no impact of diet or bodyweight identified with 
respect to the number of open (Supplementary Fig. S3A) (t24 = 1.353, p = 0.1887) and closed (Supplementary 
Fig. S3B) (t(24) = 0.0647, p = 0.9468) arm entries for the HFC, compared with the LFC. Non-parametric analy-
sis on the % of time spent in open (Mann-Whitney U value: 78.50; Wilcoxon W: 169.50 p = 0.758) and closed 
arms (t24 = 0.3962, p = 0.6955) did not reveal any impact of diet on anxiety-like behaviour (Supplementary 
Fig. S3C,D). Similarly, L. brevis had no effect on anxiety-like behaviour as measured by the % of time spent in 
open (Chi squared = 1.772; df = 2; p = 0.0412 [Kruskall-Wallis test]) and closed arms (F2,40 = 0.085, p = 0.918; 
Supplementary Fig. S3C,D).
Discussion
This exploratory study demonstrates that daily administration of GABA-producing lactobacilli has a moder-
ate efficacy in improving insulin sensitivity and glucose tolerance in metabolically dysfunctional mice. Two 
GABA-producing L. brevis strains of different origins were selected to compare their therapeutic potential in 
a mouse model of diet-induced obesity. The ability of certain lactic acid bacteria to biosynthesize GABA is a 
strain-dependent attribute, genetically governed by the genes gadB and gadC, whereby the GABA-production 
efficiencies differ between strains34,35. The GABA-production capability of L. brevis DSM32386 was comparable 
to that of L. brevis DPC6108 in vitro. However, DSM32386 appeared to have a greater impact, albeit modest, in 
improving some of the metabolic and behavioural outcomes associated with metabolic dysfunction in this mouse 
model.
GABA is synthesized from glutamate by glutamic acid decarboxylase (GAD) and is produced by pancre-
atic β-cells36. Once released, GABA binds the GABAA receptor (ligand-gated Cl− ion channel) on pancreatic 
α-cells, causing Cl− influx following membrane hyperpolarization, in turn suppressing glucagon secretion37,38. 
It has been suggested in diabetic subjects that an impaired insulin-Akt-GABAA receptor-glucagon secretory 
pathway in the islet may be an underlying mechanism for unsuppressed glucagon secretion, despite hypergly-
caemia38,39. Unlike in α-cells, GABAA receptor signalling in β-cells induces membrane depolarization, which 
opens voltage-dependent calcium channels, stimulating insulin secretion. Therefore, microbial intervention 
with GABA-producing strains has the potential to agonise GABAA receptors in the pancreas, thereby preventing 
unsuppressed glucagon secretion and stimulating insulin secretion.
In this study, 12 weeks of HF feeding was sufficient to induce glucose intolerance and insulin insensitivity. The 
results indicate that microbial intervention, particularly with L. brevis DSM32386, improved glucose homeostasis 
by attenuating diet-induced obesity associated hyperglycaemia and insulin insensitivity. During the glucose tol-
erance test, intervention with both L. brevis strains significantly enhanced insulin secretion in response to glucose 
load. This could represent an increase in the sensitivity of the endocrine response to promote glucose clearance 
following GABA-producing L. brevis intervention.
Although there were no differences in the final bodyweight gain between the HF diet fed groups, L. brevis had 
a significant effect on the distribution of adiposity. Intervention with both DSM32386 and DPC6108 resulted in 
less MAT accumulation, compared with the HFC. This is important as the oxidative phosphorylation potential 
of MAT is known to be far greater than that of SAT in humans40. Moreover, MAT mass is known to correlate well 
with the development of insulin resistance and T2D, a characteristic which SAT does not possess41. Therefore, it 
appears that GABA-secreting microbial interventions altered fat distribution in a manner which contributes ben-
eficially to metabolic fitness. Interestingly, both DSM32386 and DPC6108 also reduced percentage body fat mass, 
compared with the HFC. While these outcomes are intriguing, the mechanisms involved are not entirely clear, 
although certain probiotic bacteria have been shown to attenuate HF diet-associated weight gain and enhance 
insulin sensitivity in previous studies42,43. For example, Schneeberger et al. have demonstrated that Akkermansia 
muciniphila was negatively associated with HF feeding, correlating strongly with changes in the expression of 
lipid metabolism-related genes and inflammation markers in adipose tissue43. Modification of immune cells in 
MAT has also been associated with beneficial effects on diabetes44. While the underlying mechanisms through 
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which L. brevis reduces MAT in the host remain unknown, there is evidence to suggest that the therapeutic effects 
could be mediated by re-distribution of fat in the host, but this remains to be explored. Equally as intriguing is the 
impact of L. brevis on host lipid metabolism, as both strains were associated with reductions in fasting circulating 
cholesterol levels and an overall improvement in post-prandial cholesterolaemia. The cholesterol-lowering effects 
of certain probiotic bacteria have previously been linked with microbial bile acid modification45 and exopolysac-
charide production46,47. However, this exploratory study is the first to demonstrate a potential role of microbial 
GABA-production in addressing diet-induced hypercholesterolaemia.
We hypothesized that HF feeding would significantly affect the gut microbiota composition of the mice in this 
study. Taking a metataxanomic approach, we aimed to determine whether improvements in the metabolic profile 
following microbial intervention could be attributed to a beneficial impact on the gut microbiota. Several studies 
have characterised the gut microbiota composition of diet-induced obese mice using next generation sequencing 
methods48–51. Interestingly, there appears to be a characteristic shift in the relative abundances of the two most 
abundant phyla following obesity, whereby there is an increase in Firmicutes and a decrease in Bacteroidetes. Our 
data demonstrated that the HF diet did indeed induce alterations in the intestinal microbial composition, signif-
icantly increasing Firmicutes, with a stable abundance of Bacteroidetes in the HFC and in the groups exposed to 
L. brevis and HF diet. As a consequence, the ratio of Firmicutes to Bacteroidetes was increased following HF diet 
consumption; however, L. brevis did not mitigate this shift. Lower Firmicutes to Bacteroidetes ratios are associ-
ated with reduced blood glucose levels or increased glucose tolerance48,52. Indeed, our data reflected this by show-
ing that the LFC mice had a lower ratio of Firmicutes to Bacteroidetes and concordant glucose tolerance when 
compared with the HFC. Conversely, despite the fact that the ratio of Firmicutes to Bacteroidetes was similar to 
the HFC, intervention with DSM32386 significantly increased glucose tolerance. Actinobacteria were decreased 
in all groups fed the HF diet irrespective of microbial intervention. Deferribacteres decreased in all groups fed 
the HF diet compared with the LFC and again, microbial intervention did not significantly reverse that change. 
A high inter-group variation was observed in terms of Odoribacter abundance, although DSM32386 intervention 
trended towards a reversal. Members of the Odoribacter sp. can cause health problems in humans and animals, 
but it has been reported that they may be beneficial in the prevention of hypertension53,54 and modulating host 
blood glucose levels55,56. However, L. brevis did not modulate the genus Akkermansia and thus does not explain 
the improved metabolic profile. Despite the low relative abundance of Lactobacillus, the OTUs belonging to this 
genus were manually blasted, and the species L. brevis was only found in the DSM32386 and DPC6108 groups.
A further objective was to identify whether changes in specific microbial genera were related to any metabolic 
parameters measured during the study. Considering both microbial and metabolic factors, the LFC and L. brevis 
groups clearly separated from the HFC on PCA. Parabacteroides appeared to be related to the increase of gly-
caemia after IP-ITT, the reduction of resting insulin levels and the increase of cholesterolaemia. Bifidobacterium 
and Muribaculum were related to reduced glycaemia (upon IP-GTT and/or IP-ITT) and the reduction of cho-
lesterolaemia. Finally, Erysipelotrichaceae was related to reduced cholesterolaemia, and Odoribacter appeared 
to be related to reduced glycaemia (upon IP-GTT and/or IP-ITT). Since those genera tended to be increased 
in the LFC and L. brevis groups, respectively, they could be involved in the metabolic response of metabolically 
dysfunctional mice, although until proven, this point remains hypothetical. Nevertheless, if the gut microbiota 
changes would be the only correlation with the changes identified in the metabolic parameters, then interven-
tion with DSM32386, which had improved metabolic parameters, would have had a different microbial profile 
than DPC6108. Thus, we hypothesize that the changes in the metabolic parameters observed in DSM32386 may 
be related to the higher luminal content of GABA in the small intestine and endogenous microbial GABA pro-
duction. Therefore, alterations to the gut microbiota composition following L. brevis intervention do not solely 
explain the improvements to metabolic function.
The targeted analysis of >140 acylcarnitines, phosphatidylcholines, amino acids and biogenic amines revealed 
just two significantly altered metabolites. We observed an increase in ornithine for both microbial intervention 
groups and a decrease in arginine for DSM32386 alone. Both arginine and ornithine represent important amino 
acid metabolites in the arginine-proline metabolic pathway, which ultimately enters into the butanoate metabolic 
pathway through which GABA is synthesised in both Mus musculus and model bacterium E. coli K-12 MG1655. 
However, perhaps of greater relevance is the fact that ornithine is directly exchanged for arginine in lactobacilli in 
order to sustain the arginine deaminase pathway which contributes to GABA production57. In line with this, cul-
tures of such bacteria will invariably produce ornithine and deplete arginine from their environment. Although 
this may indeed be an important contributor to the observed result, the implications for the host remain unclear.
Mounting literature describes the role of the gut microbiota and microbial intervention in the bidirectional 
communication system of the microbiome-gut-brain axis29,58. For example, intervention with specific bacterial 
strains has proven effective in modulating behaviour and brain function in animal models ranging from meta-
bolic syndrome59,60 and depression61, to neurodevelopmental disorders such as autism62. Bacteria can produce 
a range of signalling molecules, or metabolites, including neuroactive amines and amino acids such as GABA, 
within the intestine which may signal to central and peripheral neural networks30. Obesity and stress-related psy-
chiatric disorders are frequently comorbid. Clinical data from patients with metabolic syndrome and pre-clinical 
data from animal models of obesity have demonstrated an increased risk for neuropsychiatric disorders25,26. In 
addition, maternal obesity carries significant risks for offspring in terms of metabolic disturbances and behav-
ioural deficits that manifest later in life63,64. Considering the associated risk of behavioural abnormalities asso-
ciated with obesity, we aimed to identify whether microbial GABA production in the intestine could relieve 
any behavioural abnormalities associated with obesity and metabolic dysfunction. Previously, L. rhamnosus JB-1 
induced region-dependent alterations in GABAB1β and GABAAα2 mRNA expression in a number of brain regions 
which correlated with an improvement in anxiety- and depression-related behaviour in mice30. Moreover, a recent 
clinical study investigating 16S microbiome sequencing and MRI brain scans of 23 patients suffering from major 
depressive disorder demonstrated a strong inverse correlation between relative abundances of a GABA-producing 
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taxa, Bacteroides, and a key imaging feature of the disorder65. Neither HF diet nor L. brevis intervention had any 
impact on anxiety-related behaviour as measured by the OF and EPM tests. While mice in the DSM32386 group 
produced less faecal pellets during the FST, compared to the HFC, the method of counting faecal pellets pro-
duced during the FST is a particularly crude measure of anxiety-related behaviour and is not typically used as a 
robust output from this test which has been traditionally used to assess antidepressant-like activity preclinically66. 
Furthermore, there was no effect of L. brevis on faecal pellet production in the aversive OF test and we cannot 
conclude that either strain had any effect on anxiety-like behaviour. Intervention with DSM32386 had a modest 
effect towards improving recognition memory in the NOR test. This is particularly interesting since hypergly-
caemia is a risk-factor for cognitive impairment59,67,68. One study previously demonstrated that impaired spatial 
memory in streptozotocin-induced diabetic rats was considerably improved following probiotic intervention59. 
Finally, L. brevis improved HF diet-induced behavioural despair as observed in the FST and basal corticosterone 
levels taken before the induction of FST-induced stress were lower following L. brevis intervention, compared 
with the HFC. Interestingly, the HF diet increased basal corticosterone in the HFC, compared to the LFC. This 
effect of HF feeding alone has been observed previously for both inducing despair behaviour and increasing corti-
costerone, compared to control diet69. The observation that both DPC6108 and DSM32386 reduced both despair 
behaviour and basal corticosterone levels compared to the HFC to levels which were comparable to the LFC is 
intriguing and opens the possibility that these strains could modulate brain behaviour and signalling, mediated 
through microbial GABA production.
conclusions
The data presented herein outline a potential role of metabolic- and neuroactive-microbial metabolite production 
in the modulation of diet-induced metabolic dysfunction, including abnormal behaviour. Supplementation with 
GABA-producing L. brevis increases endogenous GABA concentration in the small intestine with an impact on 
host health. Microbial modulation of the gut microbiota is a safe and effective means to modulate and improve 
health outcomes in this rodent model of obesity and metabolic dysfunction. This dataset describes that increased 
microbial GABA production can impact host metabolism and behaviour. Further substantiation of these explor-
atory health benefits in mice need to be confirmed before moving towards the clinic. This is the first study to our 
knowledge identifying a potential role of microbial GABA-production in alleviating some symptoms of metabolic 
dysfunction. Future experiments should utilise this dataset to focus on the potential mechanism of action of L. 
brevis DPC6108 and DSM32386 on the outcomes observed in this study. Furthermore, the potential for other 
metabolites to have a causative effect on the outcomes observed in this study should be explored.
Materials and Methods
Animals and treatment. All experimental procedures were performed in accordance with the protocols 
approved by the University College Cork Ethics Committee, under a license issued from the Health Products 
Regulatory Authority (AE19130/P026). Male C57BL/6J mice, three weeks of age, were obtained from Envigo 
(Blackthorn, UK) and housed under barrier-maintained conditions at the Biological Services Unit, UCC. All mice 
acclimatised to their environment for five weeks prior to administration of diets. Mice were randomly divided 
into four groups (n 14 per group) and housed in groups of three to four mice per cage at standard conditions 
(room temperature of 21 °C, with a 12-h light–dark cycle, lights on at 07:00).
The groups were assigned as follows;
Dietary intervention. A low fat (LF) group fed ad libitum with Open Source Diets (D15072701 – 10% kcal from 
fat; (Research Diets Inc., NJ 08901 USA)) and three high fat (HF) groups fed ad libitum with Open Source Diets 
(D12492 – 60% kcal from fat; Research Diets Inc.) were allowed free access to food and water, for 12 weeks. The 
compositions of the diets are outlined in Supplementary Table S1. After 12 weeks of either LF or HF feeding, two 
control groups were maintained on either the LF diet (LFC; n 14) or HF diet (HFC; n 14) for a further 12 weeks 
and the remaining two HF dietary groups were subdivided into intervention groups for a further 12 weeks.
Continued dietary intervention + microbial intervention. The HF intervention groups were as follows; (1) 
HF + L. brevis DPC6108 (1 × 1010 CFU/day; DPC6108) and (2) HF + L. brevis DSM32386 (1 × 1010 CFU/day; 
DSM32386). All interventions were administered daily in drinking water. Water containing either L. brevis 
DPC6108 or L. brevis DSM32386 was the only water supplied to the mice in these groups for the 12 week inter-
vention period and bottles were replaced daily. Bodyweight and food intake were measured weekly for all groups. 
Following 8 weeks of intervention, all mice were subjected to the behavioural test battery to measure anxiety- and 
depressive-like behaviour and cognitive function. Mice were then allowed to recover for one week and after 10 
weeks of intervention, all mice underwent the metabolic profiling battery. Following 12 weeks of intervention, 
mice were fasted overnight and body mass was measured using a Minispec mq benchtop NMR spectrometer 
(Bruker Instruments, Germany). The mice were subsequently sacrificed by cervical dislocation. All dissected tis-
sue samples were flash frozen immediately in liquid nitrogen. Individual blood samples were collected in micro-
tainerTM collection tubes containing ethylenediaminetetraacetic acid (EDTA) (BD Microtainer Plasma Separator 
Tubes, BD Diagnostics, Oxford, UK), thoroughly mixed in the tube and stored on ice for 10 min at 2,000 g under 
refrigerated conditions to isolate the plasma. Isolated plasma was immediately transferred to a clean eppendorf 
tube following centrifugation.
preparation and administration of L. brevis DPC6108 and DSM32386. L. brevis DPC6108 and 
L. brevis DSM32386 are efficient GABA producers, with maximum conversion in vitro when grown on MRS 
broth supplemented with 3% (w/v) monosodium glutamate (MSG)31. Rifampicin-resistant variants of L. brevis 
DSM32386 and L. brevis DPC6108 were isolated by spread-plating ~109 CFU from an overnight culture (1% 
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inoculum) onto MRS agar (Difco Laboratories) containing 500 µg rifampicin/mL (Sigma-Aldrich Ireland Ltd. 
Arklow, Ireland) and stocked at −80 °C. Before freeze-drying, frozen stocks were plated on MRS agar and sin-
gle colonies were isolated for inoculation in 10 mL fresh MRS broth supplemented with 30 mg/mL MSG. The 
cultures were incubated overnight at 37 °C under anaerobic conditions and then inoculated into 1 L MRS broth 
containing 3% (w/v) MSG and allowed to grow overnight at 37 °C, under anaerobic conditions. The overnight 
culture aliquots were then inoculated into large volumes of MRS containing MSG and allowed to grow overnight 
at 37 °C under anaerobic conditions. The overnight cultures were washed twice in phosphate buffered saline 
(Sigma-Aldrich Ireland Ltd.) and the pellets re-suspended in 15% (w/v) trehalose (Sigma-Aldrich Ireland Ltd.) 
in dH2O. One-millilitre aliquots of bacterial cultures were freeze-dried by using a 24-h program (freeze tem-
perature, −40 °C; condenser set point, −60 °C; vacuum set point, 600 mTorr). Freeze-dried aliquots were pre-
pared every two weeks, continuously underwent quality control checks and were stored at 4 °C until use. Vials 
of freeze-dried microbial powder were found to contain 2 × 1010 CFU following lyophilization. With an average 
calculated fluid intake of ~5 ml/mouse/day, a dose of ~1 × 109 CFU/day was achieved by suspending a single vial 
in 100 ml of distilled water. This dilution delivered a concentration of 2 × 108 CFU/ml. During re-suspension, 
100 mL of sterile water containing the freeze-dried powder was vortexed extensively to ensure solubility and even 
dispersion of the powder in water. Fresh water containing the live microorganisms was administered to mice each 
day.
culture dependent microbial analysis. To confirm that L. brevis DPC6108 and L. brevis DSM32386 
tolerated freeze-drying conditions, the strains were plated on MRS agar supplemented with rifampicin before 
and after freeze-drying. Fresh faecal samples were taken for microbial analysis to verify strain survival following 
gastric transit. A detailed description of the methods for culture dependent microbial analysis following gastric 
transit can be found in Supplementary Methods.
Metabolic profiling battery. After 12 weeks of feeding, an intraperitoneal-glucose tolerance test (IP-GTT) 
and an intraperitoneal-insulin tolerance test (IP-ITT) was performed in the LFC (n 7) and HFC (n 7) groups.
Following confirmation of metabolic disturbance in the HFC group, the IP-GTT and IP-ITT were performed 
in individual mice from groups LFC, HFC, DPC6108 and DSM32386 after 10 weeks of intervention. The insulin 
resistance index was also calculated from the plasma insulin concentrations that were measured in plasma col-
lected from tail blood during the IP-GTT and a mixed-meal tolerance test was performed, also after 10 weeks of 
intervention from individual mice in the LFC, HFC, DPC6108 and DSM32386 groups. A detailed description of 
the methods for the glucose and insulin tolerance tests, determination of insulin resistance index and the mixed 
meal tolerance test can be found in Supplementary Methods.
GABA assay. Frozen samples of epididymal adipose tissue and small intestinal content were diluted (10%, 
(w/v)) in tissue lysis solution (0.01 N HCl, 1 mM EDTA, 4 mM sodium metabisulphite (Sigma-Aldrich Ireland 
Ltd.)) and homogenised. A commercially available enzyme immunoassay was then used for the quantita-
tive determination of GABA by ELISA (ImmuSmol, Pessac, France). Quantification of unknown samples was 
achieved by comparing their absorbance with a standard curve prepared with known standards and results were 
standardised to individual sample weights.
Plasma Metabolome – direct flow injection and LC-MS/MS. Plasma was isolated from whole blood, 
as previously described and analysed using the Biocrates AbsoluteIDQ p180 Kit (BIOCRATES Life Sciences 
AG, Austria), using methods previously described70. Following extraction and derivatisation, all analytes pres-
ent in the samples were detected and quantified on an ABI 4000 Q-Trap mass spectrometer (MDS Sciex) run 
in conjunction with a reverse-phase HPLC-column. The analysis revealed levels of a range of specific amino 
acids, biogenic amines (BA), acylcarnitines (AC), lysophosphotidylcholines (lysoPC), phosphotidylcholines (PC), 
sphingomyelins (SM) and hexoses.
Microbial DNA extraction, 16S rRNA amplification and Illumina Miseq sequencing. Caecal con-
tents were collected from individual mice following 12 weeks of dietary intervention. Total metagenomic DNA was 
extracted from caecal contents with the QIamp® PowerFecal® DNA Kit (Qiagen, Milan, Italy) where an additional 
bead beating step was incorporated into the protocol. Extracted DNA was quantified using the NanoDropTM 
8000 Spectrophotometer (Thermo Fisher Scientific). Total genomic DNA was then subjected to PCR amplifi-
cation by targeting a 464-bp fragment of the 16S rRNA variable region V3-V471,72 using the specific bacterial 
primer set 341F (5′-CCTACGGGNGGCWGCAG-3′) and 806R (5′-GACTACNVGGGTWTCTAATCC-3′) with 
overhang Illumina adapters. Unique barcodes were attached to the forward primer for facilitating the differen-
tiation of samples. Amplicons were cleaned with the Agencourt AMPure kit (Beckman Coulter) following the 
manufacturer’s instructions, and DNA was quantified using the Quant-iT PicoGreen dsDNA kit (Invitrogen). 
Amplicons were mixed and combined in equimolar ratios, and the quality and purity of the library was checked 
with the High Sensitivity DNA Kit (Agilent, Palo Alto, CA, USA) by the Bioanalyzer 2100 (Agilent). The library 
was sequenced on an Illumina MiSeq platform at CIBIO (Center of Integrative Biology) – University of Trento, 
Italy. The bioinformatic analysis that was used to analyse the 16S rRNA Illumina Miseq sequencing data can be 
found in the Supplementary Methods.
Behaviour test battery. Following 20 weeks of high fat feeding and eight weeks of L. brevis intervention, 
mice from all groups underwent a behavioural test battery. A detailed description of the methods for each behav-
iour test and stress-induced corticosterone production can be found in Supplementary Methods.
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Statistical analyses. All data are expressed as mean ± SEM. Data were analysed using the appropriate 
unpaired student t-test and one-way analysis of variance (ANOVA). Bodyweight data were analysed using the 
mixed model ANOVA and Tukey’s post-hoc test was applied. Data were deemed significant when p < 0.05. Levenes 
test for homogeneity of variances was used and where homogeneity was not found, Welch’s robust test of equal-
ity of means was applied. Mauchly’s test of sphericity was used and if values were significant, then Greenhouse 
Geisser was applied. All student t-tests, one-way ANOVA, and post hoc analyses were performed using PASW 
Statistics 22. The correlation matrix of microbiota profile data and metabolic parameters was performed using 
Pearson’s Product-Moment Correlation. Graphs were generated using Graphpad Prism 7. Metabolomic data was 
log normalised prior to ANOVA and multivariate analysis (sPLS-DA) was also performed on metabolomic data. 
For metabolomic data, a false discovery rate (FDR) q value less than 0.05 was considered statistically significant.
Data availability
The data generated by Illumina sequencing were deposited in the NCBI Sequence Read Archive (SRA) and are 
available under Ac. No. PRJNA414526.
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